Skip to main
AMPH

Amphastar Pharma (AMPH) Stock Forecast & Price Target

Amphastar Pharma (AMPH) Analyst Ratings

Based on 6 analyst ratings
Hold
Strong Buy 17%
Buy 17%
Hold 67%
Sell 0%
Strong Sell 0%

Bulls say

Amphastar Pharmaceuticals Inc. has demonstrated substantial growth potential, highlighted by a 10% quarter-over-quarter increase and a 5% year-over-year rise in top-line revenue for 3Q25, totaling $191.8 million, which surpassed market expectations. The company anticipates continued growth from key products such as Baqsimi and Primatene Mist, with projections of high-single digit unit growth in 2025 and a return to double-digit growth by 2026. Additionally, the firm remains optimistic about upcoming product approvals and launches, further solidifying its positive outlook within the biopharmaceutical market.

Bears say

Amphastar Pharmaceuticals Inc. is facing significant downward pressure on its revenue forecasts due to intensifying competition in key product categories, particularly iron sucrose and glucagon, with sales expectations for iron sucrose revised downward from $60 million annually to approximately $5 million quarterly. The emergence of additional competitors in the glucagon market has further compounded challenges, leading to projections that annual sales for this product will dip below $70 million starting in 2026. Furthermore, the anticipated return to double-digit top-line growth in 2026 has been tempered, with expectations now adjusted to high-single-digit to low-double-digit growth rates, thereby indicating a more cautious outlook for the company's financial performance moving forward.

Amphastar Pharma (AMPH) has been analyzed by 6 analysts, with a consensus rating of Hold. 17% of analysts recommend a Strong Buy, 17% recommend Buy, 67% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Amphastar Pharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Amphastar Pharma (AMPH) Forecast

Analysts have given Amphastar Pharma (AMPH) a Hold based on their latest research and market trends.

According to 6 analysts, Amphastar Pharma (AMPH) has a Hold consensus rating as of Apr 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $29.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $29.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Amphastar Pharma (AMPH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.